Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
ARCHIVE
Astellas Licenses Transplant Viremia Prevention Vaccine from Vical
Astellas Pharma announced on July 15 that it concluded a license agreement with Vical Inc. of the US and obtained exclusive worldwide development and commercializing rights to Vical's TransVax, a therapeutic vaccine designed to control cytomegalovirus (CMV) viremia in transplant…
To read the full story
Related Article
- Astellas/Vical’s CMV Vaccine Flops in Global PIII
January 23, 2018
- Astellas-Vical’s CMV Vaccine Disappoints in PII for Kidney Transplant Patients
September 21, 2016
ARCHIVE
- Pharmaceutical Industry Salary Survey 2011
December 26, 2011
- AFII Grants France-Japan Investment Award to sanofi-aventis, Canon
December 19, 2011
- Plan Like Your Life Depended on It… It Just Might!
December 5, 2011
- Interviewing and Hiring: Strong Character Plus Good Attitude Equals Great Potential
November 14, 2011
- A Cry from the Next Generation of Japanese Pharmaceutical Executives
October 24, 2011
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…